Home/ Stocks/ GOVX

GeoVax Labs, Inc. New

GOVX XNAS

$0.60 +0.06 (+9.53%) ▲ 15-min delayed

Open

$0.61

High

$0.64

Low

$0.60

Volume

741.6K

Market Cap

$3.10M

About GeoVax Labs, Inc. New

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 19 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-4,426,578	$-0.97
Q1 2026	$0	$-5,261,921	$-2.62
FY 2025	$2.49M	$-21,464,771	$-22.40
Q3 2025	$0	$-6,318,914	$-0.31

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 11, 2026

Calendar →

TickerDaily Coverage

Why Is GeoVax Labs, Inc. New (GOVX) Stock Up 51.6% Today?

Penny Stocks Marcus Rivera · May 22, 2026

GeoVax Labs (GOVX) ripped 51.6% higher Friday, closing at $3.89 after the clinical-stage biotech...

View All Coverage →

Get GOVX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on GeoVax Labs, Inc. New.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.